Bradley Campbell: Yeah, thanks, Gil. In the Fabre markets, just based on the pricing dynamics, you’ve kind of historically seen a 70 to 30 distribution between ex-US and US. As you saw in our reported numbers, that’s, drifting a little bit more towards 60-40 at this point for us. And I think with Pompeii, you’ll probably continue to see that slightly larger ratio of US revenues versus ex-US revenues. I think if you look at the existing Pompeii market, it is closer, more close to that kind of 60-40 split. So yeah, I think that’s a reasonable sort of long-term expectation as the balance of our revenue comes from both Pompeii and Fabre. We’ll, of course, continue to report on that distribution of revenue. And if there’s changes and trends there, we’ll guide people that way. But I think that’s kind of a reasonable expectation for the next few years.
Operator: Thank you. Our next question comes from the line of Jeff Hung of Morgan Stanley.
Jeff Hung: Thanks for taking my question. For Pombiliti and Upfolda, can you just talk about the impact you’ve seen from KLL and patient outreach in Europe, and how does that set your expectations for the pace and the impact of your research outreach efforts in the US? You know, is there anything that you might see that’d be different in the geography that you could highlight? Thanks.
Bradley Campbell: Probably the biggest difference between Europe and the United States is, outside the United States, there’s no real opportunity to interact directly with patients, whereas in the US, you do have some medical education that can go towards the patient community. So there’s a little bit more of a direct interaction there. We also have a team of patient education liaisons who are in the field who are helping with the infusion process. You know, many of these patients do home infusions, and so that’s a slightly different dynamic as well. But by and large, you have a very active, very aware physician community, and likewise, very active, very aware patient community. And so right now, the focus from Jeff and his team, and from the commercial organization, is on educating physicians, the availability, talking about the data, etc., and generating new evidence, which we’re, you will continue to generate new publications and presence of medical congresses.
But I think also you’ll see a growing kind of word of mouth as more and more patients get, have experience with Pombiliti and Opfolda directly. I think you’ll see that start to really play a part as well, where, either a family member or somebody through the community talks about their experience and encourages others to think about that experience as well. So I think that dynamic will continue to grow as more and more new patients have access to Pombiliti and Opfolda.
Operator: Thank you. Our next question comes from the line of Salveen Richter of Goldman Sachs. Please go ahead, Salveen.
Unindentified Analyst: Hi, team. This is [indiscernible] for Salveen. Congratulations on the quarter. A couple of questions from us. Of the 75 treatment centers worldwide that have participated in the clinical trials and expanded access programs, what percentage of the patient population is covered through these 75 treatment centers? And the second question is that you mentioned that patients are already switching from existing ERTs. We understand that the numbers are small, but is there any insight you can provide on how those patients are doing once they’ve switched over to Pombiliti and Opfolda?
Bradley Campbell: Sebastian, do you want to talk about the, kind of, what percentage those top KOLs, what percentage of, of patients either flow through them or prescriptions flow through them? And then I’ll take the second question.
Sebastien Martel: Yeah. So, Pompeii is, Pompeii is, treated with a fairly concentrated HCP group on a global basis. You’ve got, differences on a country by country basis with some markets being very concentrated. The UK, for example, has six main reference centers for those lysosomal storage disease. And you’ve got, Germany at the other end of the spectrum, which is a lot more fragmented. And so, it really varies by country, in some, you, you essentially deal with a very small number of, key accounts in some way. And in others, you have to expand to a larger group, although, like you would see typically for any rare disease, we’re not talking, very broad number of physicians, in the grand scheme of things, it’s still somewhat, somewhat concentrated.
Bradley Campbell: Yeah. Thanks, Sebastian. So I think, those 75 KOLs globally, they probably influence in some way, the vast majority of treatment decisions. So, 75%, 80%, whether in the end, they actually end up being the treaters themselves, you’ve got home infusions, you’ve got, as Sebastian articulated, both Germany and the United States, you have infusion clinics, or more community based physicians that are doing the infusions. But I think those, those top KOLs influence the vast majority of treatment, thoughts and decision making, which is important. And in terms of the second one, how are, how are patients doing? I think, too early to know how the initial switch patient, if it’s first handful of weeks, we are getting very positive feedback, again, word of mouth from physicians and patients on the switch process and how they’re feeling in the initial days.
And so I think early signals are that it’s very positive. I would though, say in terms of a data, from a data perspective, you’re starting to see us present on the long term outcomes of patients from the, from the PROPEL study and from our other boluses of patients. And I think that’s where we see, we’re very confident in that long term data being durable and consistent across patients.
Operator: That was your last question. This concludes today’s conference call. Have a great day.